Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Krzysztof Potempa Profile picture
Krzysztof Potempa
@BRAINCURES
Founder & CEO @BRAINCURESLtd and dreamster dedicated to prevention and treatment of mental health disorders that affect at least 1 in 6 people worldwide
Sep 3 • 17 tweets • 6 min read
🧵 The founder of a successful public biotechnology company once told me that the secret to his company's success was neither the idea nor the concept, but the management team: from day one the company had excellent managers and the best mid-level managers
nature.com/articles/nbt06… The challenge for the manager of a biotechnology startup, especially in Europe, is to foster a transition within the founding biotech team from science-oriented to commerce-oriented thinking and action
—Andreas Föller @NatureBiotech
nature.com/articles/nbt06…
Jul 3 • 17 tweets • 7 min read
🧵 Don Selkoe, a whistleblower expert and author of Don't Kill the Messenger, says that whistleblowers are ready to endure all forms of retaliation for the sake of truth, as the truth-telling part of their brain seems to override the health and safety part
linkedin.com/pulse/survivor… Whistleblowers are not being protected enough within the academic environment. Somebody should feel comfortable to be able to raise issues without fearing retaliation or damage to their own career says @skleinert1 to @edyong209 @heidiledford @Richvn
nature.com/articles/50345…
Image
May 25 • 4 tweets • 2 min read
🧵1. Genetic support for FDA-approved drugs over the past decade
@PoRusina Maria Falaguera, Juan María Roldán Romero, Ellen McDonagh @DunhamReal @d0choa

2. Human Genetics & Genomics for Drug Target Identification & Prioritization: @OpenTargets' Perspective nature.com/articles/d4157…
Image Human Genetics and Genomics for Drug Target Identification and Prioritization: Open Targets @OpenTargets' Perspective

Ellen McDonagh, @GosiaTrynka @markmccarthyoxf @emilyroseholz @kshameer, Nikolina Nakic, Xinli Hu, @HelenaCornu, Ian Dunham, @DavidHulcoop
linkedin.com/posts/krzyszto…
Aug 18, 2023 • 100 tweets • 36 min read
🧵 A neonatal nurse has been found guilty of murdering seven babies and attempting to kill 6 more, making her the worst child serial killer in modern British history and raising urgent questions over whether her crimes could have been stopped
@joshhalliday
theguardian.com/uk-news/2023/a… Lucy Letby guilty of murdering seven babies as Angel of Death nurse at NHS hospital. She was working as a nurse at the neonatal unit at the Countess of Chester Hospital, where she was accused of murdering seven babies and trying to kill 10 others
mirror.co.uk/news/uk-news/b…
Mar 14, 2023 • 9 tweets • 5 min read
Can you imagine applying biological intelligence-BI to achieve a 3 to 5-fold increase on AstraZeneca’s reported 19% success rate in the proportion of pipeline molecules that advance from preclinical investigation to completion of Phase III clinical trials?
bioindustry.org/news-listing/m… @BraincuresLTD's biological intelligence (BI) approach eliminated 59 of 72 target-compound pairs associated with Phase III clinical failures to enable 60 to 100% likelihood of clinical success rates across compounds that target 13 different protein classes
bioindustry.org/news-listing/m…
Mar 13, 2023 • 16 tweets • 17 min read
🧵@KQLabs is a major initiative, delivered by @TheCrick supported by funding from @InnovateUK, and with collaboration from the @KQ_London @HDR_UK @GenomicsEngland, which aims to bring together a powerful eco-system in support of data-driven health startups
knowledgequarter.london/kq-labs/ Providing critical support to early stage data-driven health science startups, @KqLabs offers a customised framework with a 16-week accelerator programme. The program also includes workshops to inspire and nurture the next generation of start-ups
@TheCrick
crick.ac.uk/news/2018-09-1…
Mar 13, 2023 • 7 tweets • 7 min read
🧵 @miramurati is a name that is gaining recognition in the world of artificial intelligence (AI). She is the brain behind the development of @OpenAI's ChatGPT, an #AI language model that has revolutionized the way we interact with machines @GlobalWomanCo
globalwomanmagazine.com/mira-murati-th… ChatGPT is essentially a large conversational model—a big neural net that’s been trained to predict the next word—and the challenges with it are similar challenges we see with the base large language models: it may make up facts
@MiraMurati CTO @OpenAI #AI
time.com/6252404/mira-m…
Mar 11, 2023 • 12 tweets • 8 min read
Greg Becker, the CEO of Silicon Valley Bank sold $3.57 million of stock at an average price of $287.42 in a sell-off two weeks before it collapsed. CFO Daniel Beck ditched $575,000. The price plunged to just $39.49 before the FDIC seized the bank's assets
dailymail.co.uk/news/article-1… Federal Deposit Insurance Corporation @FDICgov, which typically protects deposits up to $250,000, said it had taken charge of the roughly $175bn (£145bn) in deposits held at the Silicon Valley Bank, the 16th largest in the US @shermannatalie @JamesClayton5
bbc.co.uk/news/business-…
Mar 11, 2023 • 6 tweets • 14 min read
Women in Innovation Programme was launched in 2016 by @innovateuk with the overall aim of increasing gender equality in business-led innovation. The annual competition supports and celebrates remarkable #women entrepreneurs & senior business leaders @KTNUK
iuk.ktn-uk.org/programme/wome… #WomenInInnovation
Katerina Spranger-@OxfordHeartbeat
Claire Trant-Untap
@lornuccia-Phyona
Monika Tomecka-@uFraction8
@LydiaMapstone-@BoobyBiome
Louise Ben-Nathan-@LBNInnovations
Divia Bhatnagar-Medical Intelligence Group
@JoBarrow-Curb Health
@KTNUK #SDG5
iuk.ktn-uk.org/programme/wome…
Dec 17, 2022 • 4 tweets • 3 min read
@KaterinaGalai, spoke to @SamBarrell1 about her career as an accomplished healthcare leader, including her leadership role at Europe’s largest single-site biomedical research organisation, the Francis Crick Institute @TheCrick, during the COVID-19 pandemic
cogconsortium.uk/women-in-cog-i… Sam “only ever planned one thing…and that was to be a doctor. For me, it’s just about being open-minded, enjoying challenges and being able to overcome them.” @SamBarrell1 prioritises one factor when considering a position: “they have to be purpose-led.”
Dec 16, 2022 • 14 tweets • 7 min read
885 of all small molecule drugs pass the rule-of-five test; of these, 619 (70%) are actually dosed orally, whereas 159 (20%) of orally dosed drugs fail at least one of the rule-of-five parameters
-John P Overington, Bissan Al-Lazikani and Andrew L Hopkins
nature.com/articles/nrd21… @johnpoverington et al determine that all current drugs with a known mode-of-action act through 324 distinct molecular drug targets. 266 are human-genome-derived proteins, and the remainder are bacterial, viral, fungal or other pathogenic organism targets
readcube.com/articles/10.10…
Dec 13, 2022 • 12 tweets • 7 min read
Psychologist Dr. Lee-Anne Gray founded a school whose mission is “Empathic Education for a Compassionate Nation.” She teaches the art of empathic listening and it is a powerful technique to dismantle normalized bullying in our society @bulliedbrain #resist
psychologytoday.com/ca/blog/the-bu… Identifying with the aggressor is comparable to Stockholm syndrome, in which a hostage will bond with their captor. This bonding occurs because the brain is aware that the captor could harm or kill the #hostage. The bond intensifies as a survival strategy
psychologytoday.com/ca/blog/the-bu…
Dec 12, 2022 • 13 tweets • 8 min read
In 2018, @pfizer had turned to Kathrin and her research team to identify a partnership that would advance mRNA development for a game-changing seasonal flu vaccine. During the #partnership search, she made fast friends with the Turkish-German cofounder and BioNTech CEO Ugur Sahin Pfizer signed a collaboration agreement to codevelop a first-in-class, mRNA-based coronavirus vaccine, aimed at preventing COVID-19 infection. BioNTech received $72 million up-front & was eligible for future milestone payments of an additional $563 million
amazon.com/Moonshot-Pfize…
Dec 11, 2022 • 8 tweets • 6 min read
The myopic focus of companies on profits has been criticized in recent years. Mads Øvlisen, the former CEO of @NovoNordisk, explains how the pursuit of a corporate purpose beyond short-term profits, can actually lead to higher long-term profits @TimaBansal
forbes.com/sites/timabans… Corporate purpose isn’t just about vision and values, it’s about keeping an eye on the long term. Upholding #corporate purpose requires leaders to resist the short-term demands of shareholders & investors in order to build good & successful companies #CSR
forbes.com/sites/timabans…
Dec 5, 2022 • 6 tweets • 4 min read
🧵 What kind of vaccine are you hoping for?

@JeremyFarrar: (laughs) If I knew, I'd be a @NobelPrize candidate–or a multibillionaire...
It would be a once-in-a-lifetime vaccine like the one against measles,
it would cost a cent,
it would block transmission
spiegel.de/international/… Is it still possible to find a vaccine for this soup of different variants?
@JeremyFarrar: We have to get ourselves out of that situation. And I think the only way we're going to get ourselves out of that is the generation of vaccines
@bredow @VHackenbroch
Dec 4, 2022 • 7 tweets • 4 min read
We have tested the antibody in various doses on 856 patients on 3 continents. After only 6 months we observed positive results, and after 18 months 81% of the group receiving the highest dosage showed lower levels of amyloid beta than the level we measure in Alzheimer’s-Lannfelt “The idea for the antibody originated back in the 1990s, when the team identified a change in the genetic material of a Swedish family that had been severely afflicted by Alzheimer's disease. The mutation indicated that the cause seemed to be protofibrils”
medicalxpress.com/news/2018-10-a…
Dec 4, 2022 • 8 tweets • 7 min read
“I hope that Dr. Tessier-Lavigne will not brush off these concerns as irrelevant. There appear to be a lot of visible errors in these papers, and some duplications are suggestive [of] an intention to mislead,” @MicrobiomDigest
@deemostofi @StanfordDaily
stanforddaily.com/2022/11/29/sta… The @StanfordDaily reached out to Science and @Nature, where another of Tessier-Lavigne’s papers containing alleged data alteration was published, for comment. @ScienceMagazine's editor-in-chief @hholdenthorp wrote in an email that he would “check around.”
Dec 4, 2022 • 4 tweets • 4 min read
Right now, we're going after the pathology of the disease–plaques & tangles-but I think we need to start going after the biology and, as a result, the pharmacology that addresses the altered biology with aging that occurs in Alzheimer's-@a_hfillit @TheADDF
biospace.com/article/ctad-2… “Lecanemab slows #cognitivedecline. But this is only a start to stopping Alzheimer’s in its tracks. We have a lot of ground to cover to get from the 27% slowing #lecanemab offers to our goal of slowing cognitive decline by 100%"-@a_hfillit on #CTAD22 data
alzdiscovery.org/news-room/anno…
Dec 3, 2022 • 5 tweets • 5 min read
Today, almost half of the 4 million Americans living with type 1 diabetes use devices called continuous glucose monitors, or CGMs, to monitor their #glucose levels and regulate their insulin levels in real-time.
@statnews' @KatieMPalmer reviews CGM's here:
reports.statnews.com/products/conti… @statnews unpacks the differences between the different ways the FDA approves drugs, like accelerated approvals, fast-track designations, and emergency use authorizations. It touches on how we got here, where the agency is headed next, and what's at stake
reports.statnews.com/products/speed…
Dec 3, 2022 • 7 tweets • 4 min read
🧵Since the first β-lactam, aminoglycoside, macrolide, tetracycline, and fluoroquinolone classes of antibiotics were discovered and approved from 1940 to 1980, few #antibiotics with novel mechanisms of action have been developed
@thomasmd @akesselheim #AMR
science.org/doi/10.1126/sc… Phase III clinical trials of a antibiotic in a single disease indication cost about US$70 million. Funding for biotech companies—venture capital or government grants—cannot cover this for a drug that will be sold mainly in short courses
Cooper M & Shlaes D
nature.com/articles/47203…
Dec 3, 2022 • 5 tweets • 4 min read
After 18 months, participants who received lecanemab scored, on average, 0.45 points better on the CDR-SB than those who got a placebo. Some researchers, however, have questioned whether this shift is big enough to make a noticeable difference in a person’s symptoms @meprillaman It’s a modest benefit, says @BrentForester, director of the Geriatric Psychiatry Research Program @McLeanHospital who helped to run the clinical trial for lecanemab. His concerns lie with safety. About 20% of treated people had brain-scan anomalies
#CTAD22